




FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

STEVEN L. HIGHLANDER
PARTNER
SHIGHLANDER@FULBRIGHT.COM

DIRECT DIAL: (512) 536-3184
TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

March 16, 2004

| | |
|---|---|
| CERTIFICATE OF MAILING 37 C.F.R. 1.8 | |
| I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Box Sequence, Commissioner for Patents, P.O. Box 2327, Arlington, VA 22202, on the date below: | |
| March 16, 2004 |  |
| Date | Steven L. Highlander |

MS DD
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Re: *U.S. Patent Application No. 10/752,380 entitled, "EBV CTL EPITOPES" by Rajiv Khanna et al.*
Our Ref. No. FBRC:008USC3
Client Ref. No. 502023/MRO


Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement and Form PTO-1449.

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/FBRC:08USC3.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,


Steven L. Highlander
Reg. No. 37,642

SLH/cas
Encl.: as noted



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Rajiv Khanna et al.

Serial No.: 10/752,380


Filed: January 6, 2004

For: EBV CTL EPITOPES

Group Art Unit: Unknown

Examiner: Unknown

Atty. Dkt. No.: FBRC:008USC3

| CERTIFICATE OF MAILING 37 C.F.R. 1.8 | |
|--|---|
| I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below. | |
| March 16, 2004 |  |
| Date | Steven L. Highlander |

INFORMATION DISCLOSURE STATEMENT

MS DD

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record.


In accordance with 37 C.F.R. §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/FBRC:008USC3.

This application is a continuation application of Serial No. 09/194,450, filed June 25, 1999 and is relied upon for an earlier filing date under 35 U.S.C. § 120. In accordance with Rule 37 C.F.R. § 1.98(d) copies of the listed documents are not enclosed as they have been previously cited by or submitted to the Patent and Trademark Office in prior application Serial No. 09/194,450.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Steven L. Highlander
Reg. No. 37,642
Attorney for Applicant

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: March 16, 2004

Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.

FBRC:008USC3

Serial No.

10/752,380

Applicants

Rajiv Khanna *et al.*

Filing Date:

January 6, 2004

Group:

Unknown

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

| Exam. Init. | Ref. Des. | Document Number | Date | Name | Class | Sub Class | Filing Date if App. |
|-------------|-----------|-----------------|------|------|-------|-----------|---------------------|
| | | | | | | | |

Foreign Patent Documents

| Exam. Init. | Ref. Des. | Document Number | Date | Country | Class | Sub Class | Translation Yes/No |
|-------------|-----------|-----------------|---------|---------|-------|-----------|--------------------|
| | B1 | WO 95/24925 | 9/21/95 | PCT | | | |

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|---|
| | C1 | Addinger <i>et al.</i> , "A putative transforming gene of Jijoye virus differs from that of Epstein-Barr virus prototypes," <i>Virology</i> , 141:221-234, 1985. |
| | C2 | Andrew <i>et al.</i> , "The roles of influenza virus haemagglutinin and nucleoprotein in protection: analysis using vaccinia virus recombinants," <i>Scand. J. Immunol.</i> , 25:21-28, 1987. |
| | C3 | Apolloni <i>et al.</i> , "Sequence variation of cytotoxic T cell epitopes in different isolates of Epstein-Barr virus," <i>European Journal of Immunology</i> , 22:183-189, 1992. |
| | C4 | Apolloni and Sculley, "Detection of A-type and B-type Epstein-Barr virus in throat washings and lymphocytes," <i>Virology</i> , 202:978-981, 1994. |
| | C5 | Bogedain <i>et al.</i> , "Specific cytotoxic T lymphocytes recognize the immediate-early transactivator Zta of Epstein-Barr virus," <i>J. Virol.</i> , 69:4872-4879, 1995. |
| | C6 | Brooks <i>et al.</i> , "Different HLA-B27 subtypes present the same immunodominant Epstein-Barr virus peptide," <i>J. Exp. Med.</i> , 178:879-887, 1993. |
| | C7 | Buisson <i>et al.</i> , "Changes in the dominant Epstein-Barr virus type during human immunodeficiency virus infection," <i>J. Gen. Virol.</i> , 75:431-437, 1994. |
| | C8 | Burrows <i>et al.</i> , "An Epstein-Barr virus-specific cytotoxic T-cell epitope present on A- and B-type transformants," <i>Journal of Virology</i> , 64(8):3974-3976, 1990. |
| | C9 | Burrows <i>et al.</i> , "Bystander apoptosis induced by CD8+ cytotoxic T cell (CTL) clones: implications for CTL lytic mechanisms," <i>Int. Immunol.</i> , 5:1049-1058, 1993. |

25381873.1

Examiner:**Date Considered:**

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | | |
|--|---|--|--------------------------|
| Form PTO-1449 (modified) | | Atty. Docket No. FBRC:008USC3 | Serial No. 10/752,380 |
| List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | Applicants Rajiv Khanna <i>et al.</i> | |
| | | Filing Date: January 6, 2004 | Group: Unknown |
| U.S. Patent Documents <i>See Page 1</i> | Foreign Patent Documents <i>See Page 1</i> | Other Art <i>See Page 1</i> | |

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|---|
| | C10 | Burrows <i>et al.</i> , "The specificity of recognition of a cytotoxic T lymphocyte epitope," <i>Eur. J. Immunol.</i> , 22:191-195, 1992. |
| | C11 | Burrows <i>et al.</i> , "Five new cytotoxic T cell epitopes identified within Epstein-Barr virus nuclear antigen 3," <i>J. Gen. Virol.</i> , 75:2489-2493, 1994. |
| | C12 | Crawford <i>et al.</i> , "Epstein-Barr virus nuclear antigen positive lymphoma after cyclosporin A treatment in patient with renal allograft," <i>Lancet</i> , 1:1355-1356, 1980. |
| | C13 | Dambaugh <i>et al.</i> , "U2 region of Epstein-Barr virus DNA may encode Epstein-Barr nuclear antigen 2," <i>Proc. Natl. Acad. Sci. USA</i> , 81:7632-7636, 1984. |
| | C14 | Doherty <i>et al.</i> , "Evasion of host immune responses by tumours and viruses," <i>Ciba. Found. Symp.</i> , 187:245-260, 1994. |
| | C15 | Fazekas de St. Groth, "The evaluation of limiting dilution assays," <i>J. Immunol. Methods</i> , 49:R11-23, 1982. |
| | C16 | Gavioli <i>et al.</i> , "Multiple HLA A11-restricted cytotoxic T-lymphocyte epitopes of different immunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4," <i>J. Virol.</i> , 67:1572-1578, 1993. |
| | C17 | Gratama <i>et al.</i> , "Detection of multiple 'Ebnotypes' in individual Epstein-Barr virus carriers following lymphocyte transformation by virus derived from peripheral blood and oropharynx," <i>J. Gen. Virol.</i> , 75:85-94, 1994. |
| | C18 | Gregory <i>et al.</i> , "Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line," <i>J. Gen. Virol.</i> , 71:1481-1495, 1990. |
| | C19 | Henle <i>et al.</i> , "Rheumatoid factor as a cause of positive reactions in tests for Epstein-Barr virus-specific IgM antibodies," <i>Clin. Exp. Immunol.</i> , 36:415-422, 1979. |
| | C20 | Henle and Henle, "Seroepidemiology of the virus," In: <i>The Epstein-Barr Virus</i> , Epstein and Achong (eds.), 61-78, 1979. |
| | C21 | Hill <i>et al.</i> , "Characterization of two Epstein-Barr virus epitopes restricted by HLA-B7," <i>Eur. J. Immunol.</i> , 25:18-24, 1995. |
| | C22 | Hill <i>et al.</i> , "Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV) nuclear antigens fail to lyse the EBV-transformed B lymphoblastoid cell lines against which they were raised," <i>J. Exp. Med.</i> , 181:2221-2228, 1995. |

25381873.1

| | |
|---|-------------------------|
| Examiner: | Date Considered: |
| EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

| | | | |
|--|---|--|--------------------------|
| Form PTO-1449 (modified) | | Atty. Docket No. FBRC:008USC3 | Serial No. 10/752,380 |
| List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | Applicants Rajiv Khanna <i>et al.</i> | |
| | | Filing Date: January 6, 2004 | Group: Unknown |
| U.S. Patent Documents <i>See Page 1</i> | Foreign Patent Documents <i>See Page 1</i> | Other Art <i>See Page 1</i> | |

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|---|
| | C23 | Fu <i>et al.</i> , "Variable expression of latent membrane protein in nasopharyngeal carcinoma can be related to methylation status of the Epstein-Barr virus BNLF-1 5'-flanking region," <i>J. Virol.</i> , 65:1558-1567, 1991. |
| | C24 | Kerdiles <i>et al.</i> , "cDNA cloning and transient expression of the Epstein-Barr virus-determined nuclear antigen EBNA3B in human cells and identification of novel transcripts from its coding region," <i>J. Virol.</i> , 64:1812-1816, 1990. |
| | C25 | Kerr <i>et al.</i> , "Identification of type B-specific and cross-reactive cytotoxic T-lymphocyte responses to Epstein-Barr virus," <i>Journal of Virology</i> , 70(12):8858-8864, 1996. |
| | C26 | Khanna <i>et al.</i> , "Localization of Epstein-Barr virus cytotoxic T-cell epitopes using recombinant vaccinia: implications for vaccine development," <i>J. Exp. Med.</i> , 176:169-176, 1992. |
| | C27 | Khanna <i>et al.</i> , "Immune regulation in Epstein-Barr virus-associated diseases," <i>Microbiol. Rev.</i> , 59:387-405, 1995. |
| | C28 | Khanna <i>et al.</i> , "Expression of Epstein-Barr virus nuclear antigens in anti-IgM-stimulated B cells following recombinant vaccinia infection and their recognition by human cytotoxic T-cells," <i>Immunology</i> , 74:504-510, 1991. |
| | C29 | Khanna <i>et al.</i> , "Isolation of cytotoxic T lymphocytes from healthy seropositive individuals specific for peptide epitopes from Epstein-Barr virus nuclear antigen 1: implications for viral persistence and tumor surveillance," <i>Virology</i> , 214:633-637, 1995). |
| | C30 | Kyaw <i>et al.</i> , "Expression of B-type Epstein-Barr virus in HIV-infected patients and cardiac transplant recipients," <i>AIDS Res. Hum. Retroviruses</i> , 8:1869-1874, 1992. |
| | C31 | Landau <i>et al.</i> , "Presence of infective Epstein-Barr virus in the urine of patients with infectious mononucleosis," <i>J. Med. Virol.</i> , 44:229-233, 1994. |
| | C32 | Laroche <i>et al.</i> , "Measurement by the polymerase chain reaction of the Epstein-Barr virus load in infectious mononucleosis and AIDS-related non-Hodgkin's lymphomas," <i>J. Med. Virol.</i> , 46:66-74, 1995. |
| | C33 | Lear <i>et al.</i> , "The Epstein-Barr virus (EBV) nuclear antigen 1 BamHI F promoter is activated on entry of EBV-transformed B cells into the lytic cycle," <i>J. Virol.</i> , 66:7461-7468, 1992. |
| | C34 | Lee <i>et al.</i> , "HLA A2.1 restricted cytotoxic T-cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2," <i>J. Virol.</i> , 67:7428-7435, 1993. |

25381873.1

Examiner:**Date Considered:**

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | | |
|--|---|--|--------------------------|
| Form PTO-1449 (modified) | | Atty. Docket No. FBRC:008USC3 | Serial No. 10/752,380 |
| List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | Applicants Rajiv Khanna <i>et al.</i> | |
| | | Filing Date: January 6, 2004 | Group: Unknown |
| U.S. Patent Documents <i>See Page 1</i> | Foreign Patent Documents <i>See Page 1</i> | Other Art <i>See Page 1</i> | |

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|--|
| | C35 | Lewin <i>et al.</i> , "Characterization of EBV-carrying B-cell populations in healthy seropositive individuals with regard to density, release of transforming virus and spontaneous outgrowth," <i>Int. J. Cancer</i> , 39:472-476, 1987. |
| | C36 | Lung <i>et al.</i> , "Epstein-Barr virus genotypes associated with nasopharyngeal carcinoma in southern China," <i>Virology</i> , 177:44-53, 1990. |
| | C37 | Miller <i>et al.</i> , "An integral membrane protein (Iimp2) blocks reactivation of Epstein-Barr virus from latency following surface immunoglobulin crosslinking," <i>Proc. Natl. Acad. Sci. USA</i> , 91:772-776, 1994. |
| | C38 | Miller and Hutt-Fletcher, "A monoclonal antibody to glycoprotein gp85 inhibits fusion but not attachment of Epstein-Barr virus," <i>J. Virol.</i> , 62:2366-2372, 1988. |
| | C39 | Misko <i>et al.</i> , "Factors influencing the human cytotoxic T-cell response to autologous lymphoblastoid cell lines <i>in vitro</i> ," <i>Clin. Immunol. Immunopathol.</i> , 32:285-297, 1984. |
| | C40 | Miyashita <i>et al.</i> , "A novel form of Epstein-Barr virus latency in normal B cells <i>in vivo</i> ," <i>Cell</i> , 80:593-601, 1995. |
| | C41 | Morgan <i>et al.</i> , "A recombinant adenovirus expressing an Epstein-Barr virus (EBV) target antigen can selectively reactivate rare components of EBV cytotoxic T-lymphocyte memory <i>in vitro</i> ," <i>J. Virol.</i> , 70:2394-2402, 1996. |
| | C42 | Moss <i>et al.</i> , "Cytotoxic T-cell clones discriminate between A- and B-type Epstein-Barr virus transformants," <i>Nature</i> , 331:719-721, 1988. |
| | C43 | Moss <i>et al.</i> , "Long-term T-cell-mediated immunity to Epstein-Barr virus in man. Complete regression of virus-induced transformation in cultures of seropositive donor leukocytes," <i>Int. J. Cancer</i> , 22:662-668, 1978. |
| | C44 | Murray <i>et al.</i> , "Identification of target antigens for the human cytotoxic T-cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies," <i>J. Exp. Med.</i> , 176:157-168, 1992. |
| | C45 | Murray <i>et al.</i> , "Human cytotoxic T-cell responses against Epstein-Barr virus nuclear antigens demonstrated by using recombinant vaccinia viruses," <i>Proc. Natl. Acad. Sci. USA</i> , 87:2906-2910, 1990. |
| | C46 | Nilsson <i>et al.</i> , "The establishment of lymphoblastoid lines from adult and fetal human lymphoid tissue and its dependence on EBV," <i>Int. J. Cancer</i> , 8:443-450, 1991. |

25381873.1

Examiner:

Date Considered:

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | | |
|--|---|--|--------------------------|
| Form PTO-1449 (modified) | | Atty. Docket No. FBRC:008USC3 | Serial No. 10/752,380 |
| List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | Applicants Rajiv Khanna <i>et al.</i> | |
| | | Filing Date: January 6, 2004 | Group: Unknown |
| U.S. Patent Documents <i>See Page 1</i> | Foreign Patent Documents <i>See Page 1</i> | Other Art <i>See Page 1</i> | |

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|---|
| | C47 | Okano <i>et al.</i> , "Severe chronic active Epstein-Barr virus infection syndrome," <i>Clin. Microbiol. Rev.</i> , 4:129-135, 1991. |
| | C48 | Polack <i>et al.</i> , "A complete set of overlapping cosmid clones of M-ABA virus derived from nasopharyngeal carcinoma and its similarity to other Epstein-Barr virus isolates," <i>Gene</i> , 27:279-288, 1984. |
| | C49 | Pope <i>et al.</i> , "Burkitt lymphoma in New Guinea: establishment of a line of lymphoblasts <i>in vitro</i> and description of their fine structure," <i>J. Natl. Cancer Inst.</i> , 39:933-945, 1967. |
| | C50 | Pope <i>et al.</i> , "Transformation of foetal human leucocytes <i>in vitro</i> by filtrates of a human leukaemic cell line containing herpes-like virus," <i>Int. J. Cancer</i> , 3:857-865, 1968. |
| | C51 | Rammensee <i>et al.</i> , "MHC ligands and peptide motifs: first listing," <i>Immunogenetics</i> , 41:178-228, 1995. |
| | C52 | Ressing <i>et al.</i> , "Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through <i>in vivo</i> and <i>in vitro</i> immunogenicity studies of HLA-A 0201-binding peptides," <i>J. Immunol.</i> , 154:5934-5943, 1995. |
| | C53 | Rickinson <i>et al.</i> , "T-cell mediated regression of spontaneous and of Epstein-Barr virus-induced B-cell transformation <i>in vitro</i> : studies with cyclosporin A," <i>Cell. Immunol.</i> , 87:646-658, 1984. |
| | C54 | Rickinson <i>et al.</i> , "Influence of the Epstein-Barr virus nuclear antigen EBNA 2 on the growth phenotype of virus-transformed B cells," <i>J. Virol.</i> , 61:1310-1317, 1987. |
| | C55 | Rooney <i>et al.</i> , "Paired Epstein-Barr virus-carrying lymphoma and lymphoblastoid cell lines from Burkitt's lymphoma patients: comparative sensitivity to non-specific and to allo-specific cytotoxic responses <i>in vitro</i> ," <i>Int. J. Cancer</i> , 34:339-348, 1984. |
| | C56 | Rooney <i>et al.</i> , "Epstein-Barr virus-positive Burkitt's lymphoma cells not recognized by virus-specific T-cell surveillance," <i>Nature</i> , 317:629-631, 1985. |
| | C57 | Rosenberg <i>et al.</i> , "Biological activity of recombinant human interleukin-2 produced in <i>E. coli</i> ," <i>Science</i> , 223:1412-1414, 1984. |
| | C58 | Sample and Kieff, "Transcription of the Epstein-Barr virus genome during latency in growth-transformed lymphocytes," <i>J. Virol.</i> , 64:1667-1674, 1990. |

25381873.1

Examiner:**Date Considered:**

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | | |
|--|---|--|--------------------------|
| Form PTO-1449 (modified) | | Atty. Docket No. FBRC:008USC3 | Serial No. 10/752,380 |
| List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | Applicants Rajiv Khanna <i>et al.</i> | |
| | | Filing Date: January 6, 2004 | Group: Unknown |
| U.S. Patent Documents <i>See Page 1</i> | Foreign Patent Documents <i>See Page 1</i> | Other Art <i>See Page 1</i> | |

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|--|
| | C59 | Schmidt <i>et al.</i> , "Nonresponsiveness to an immunodominant Epstein-Barr virus-encoded cytotoxic T-lymphocyte epitope in nuclear antigen 3A: implications for vaccine strategies," <i>Proc. Natl. Acad. Sci. USA</i> , 88:9478-9482, 1991. |
| | C60 | Sculley <i>et al.</i> , "Coinfection with A- and B-type Epstein-Barr virus in human immunodeficiency virus-positive subjects," <i>J. Infect. Dis.</i> , 162:643-648, 1990. |
| | C61 | Sculley <i>et al.</i> , "Expression of Epstein-Barr virus nuclear antigens 3, 4 and 6 are altered in cell lines containing B-type virus," <i>Virology</i> , 171:401-408, 1989. |
| | C62 | Selin <i>et al.</i> , "Cross-reactivities in memory cytotoxic T lymphocyte recognition of heterologous viruses," <i>J. Exp. Med.</i> , 179:1933-1943, 1994. |
| | C63 | Sixbey <i>et al.</i> , "Detection of a second widespread strain of Epstein-Barr virus," <i>Lancet</i> , 2:761-765, 1989. |
| | C64 | Silins <i>et al.</i> , "Isolation of Epstein-Barr virus genomes using pulse-field gel electrophoresis," <i>Nucleic Acids Res.</i> , 20:2901, 1992. |
| | C65 | Sumaya and Ench, "Epstein-Barr virus infectious mononucleosis in children. Clinical and general laboratory findings," <i>Pediatrics</i> , 75:1003-1010, 1985. |
| | C66 | Sumaya and Ench, "Epstein-Barr virus infectious mononucleosis in children. Heterophil antibody and viral-specific responses," <i>Pediatrics</i> , 75(6):1011-1019, 1985. |
| | C67 | Tomkinson <i>et al.</i> , "Activated lymphocytes during acute Epstein-Barr virus infection," <i>J. Immunol.</i> , 139:3802-3807, 1987. |
| | C68 | Tussey <i>et al.</i> , "Different MHC class I alleles compete for presentation of overlapping viral epitopes," <i>Immunity</i> , 3:65-77, 1995. |
| | C69 | Wagner <i>et al.</i> , "Detection and quantification of latently infected B lymphocytes in Epstein-Barr virus-seropositive, healthy individuals by polymerase chain reaction," <i>J. Clin. Microbiol.</i> , 30:2826-2829, 1992. |

25381873.1

Examiner:

Date Considered:

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.